Answers are grounded in this paper and cite their sources.
Background: This systematic review and meta-analysis assessed the data from cohort studies that compared treatment with or without incretins and the incidence of breast cancer (BC) due to the current controversies. Methods: PubMed, Scopus, EMBASE, Cochrane, ProQuest, Ovid, and Google Scholar were searched for relevant studies. A secondary analysis was conducted to compare the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4Is) on BC development. Results: The meta-analysis of four studies with 58,767 patients and 461,475 controls revealed that incretin-based therapies increase the incidence of BC insignificantly (risk ratio (RR)=1.23, 95% confidence interval (CI)=0.44–3.40; P=0.69). The DPP-4I group significantly reduced the risk of BC compared to the GLP-1RA group (RR=0.43, 95% CI=0.32–0.59; P<0.00001). Conclusion: This study found no evidence of a substantial increase in BC incidence in patients with type 2 diabetes taking GLP-1RAs and DPP-4Is. However, DPP-4Is were less likely than GLP-1RAs to cause BC formation.
No takes yet. Share an insight, caveat, or question.
Oladghaffari et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: